Is the current treatment plan of atomoxetine for ADHD combined with lamotrigine appropriate for a patient with ADHD, binge‑eating disorder, and anxiety?

Treatment Plan Assessment: Atomoxetine + Lamotrigine for ADHD, Binge-Eating Disorder, and Anxiety

This treatment plan is partially appropriate but incomplete—atomoxetine is well-supported for ADHD with comorbid anxiety, but neither medication adequately addresses the binge-eating disorder, which requires specific evidence-based treatment.

Atomoxetine for ADHD with Comorbid Anxiety

Atomoxetine is an appropriate choice for this patient's ADHD and anxiety combination. The FDA label specifically demonstrates that atomoxetine does not worsen anxiety in patients with ADHD and comorbid anxiety disorders 1. Two controlled trials showed atomoxetine maintained anxiety stability: a 12-week pediatric trial (ages 8-17) and a 16-week adult trial demonstrated no worsening on validated anxiety scales (PARS and LSAS respectively) 1.

Multiple studies confirm atomoxetine's dual benefit:

• A 2022 systematic review concluded atomoxetine reduces anxiety symptoms in children and adolescents with ADHD 2
• A 2018 randomized controlled trial (n=136) showed atomoxetine improved both ADHD symptoms and anxiety, with greatest anxiety improvement in patients with formal anxiety disorders 3
• A 2007 double-blind study specifically in pediatric ADHD with comorbid anxiety (n=176) demonstrated significant improvement in both ADHD (ADHDRS-IV-PI) and anxiety (PARS) scores compared to placebo 4

Key advantage: Atomoxetine avoids the potential anxiety exacerbation that can occur with stimulants, making it particularly suitable for this comorbid presentation.

Lamotrigine: Unclear Indication

The rationale for lamotrigine in this case is not evident from the clinical presentation. Lamotrigine is primarily indicated for:

• Bipolar disorder depressive episodes 5
• Seizure disorders
• Mood stabilization

Unless this patient has bipolar disorder (not mentioned in the question), lamotrigine lacks clear justification. If prescribed for mood instability or emotional dysregulation, this represents off-label use without strong evidence in the context of ADHD and anxiety alone.

Critical Gap: Binge-Eating Disorder Treatment

The most significant deficiency in this treatment plan is the absence of evidence-based treatment for binge-eating disorder. The 2023 APA Eating Disorders Guideline provides clear recommendations 6:

First-Line Treatment for Binge-Eating Disorder:

• Eating disorder-focused cognitive-behavioral therapy (CBT) or interpersonal therapy (1C recommendation—strongest level)
• These should be delivered in individual or group formats

Pharmacological Options:

If psychotherapy alone is insufficient or the patient prefers medication, the guideline suggests (2C):

• Lisdexamfetamine (the only FDA-approved medication for binge-eating disorder)
• Antidepressant medications

Notably, a 2024 review specifically identifies both lisdexamfetamine and atomoxetine as medications that can address both ADHD and binge-eating disorder 5. This suggests atomoxetine may provide some benefit for binge-eating, though it lacks FDA approval for this indication.

Recommended Treatment Algorithm

Step 1: Confirm Diagnoses

• Verify ADHD meets DSM-5 criteria with functional impairment in multiple settings 7
• Confirm anxiety disorder subtype (generalized, social, separation)
• Assess binge-eating disorder severity and frequency
• Rule out bipolar disorder to determine if lamotrigine is appropriate

Step 2: Prioritize Treatment Targets

Given the comorbidity complexity, sequence interventions based on greatest impairment and risk:

If binge-eating disorder causes significant medical/psychological impairment:

1. Initiate eating disorder-focused CBT immediately 6
2. Continue atomoxetine for ADHD/anxiety (addresses 2 of 3 conditions) 1, 2, 4
3. Consider switching to lisdexamfetamine if atomoxetine provides inadequate response for either ADHD or binge-eating after 6-8 weeks 6, 5

If ADHD/anxiety are primary concerns:

1. Continue atomoxetine (well-supported for this combination) 1, 4
2. Add eating disorder-focused psychotherapy concurrently 6
3. Monitor for improvement in all three conditions over 12 weeks

Step 3: Address Lamotrigine

• If no bipolar disorder diagnosis exists, taper and discontinue lamotrigine unless there's documented benefit for mood instability
• If bipolar disorder is present, continue lamotrigine as appropriate mood stabilizer 5

Step 4: Monitoring and Adjustment

• Screen for suicidal ideation closely, especially in adolescents, as atomoxetine carries a black box warning for increased suicidal ideation risk in this population 1
• Assess ADHD symptoms, anxiety levels, and binge-eating frequency at each visit
• If inadequate response by 12 weeks, consider lisdexamfetamine as it addresses both ADHD and binge-eating disorder with FDA approval 6, 5

Common Pitfalls to Avoid

1. Neglecting psychotherapy for binge-eating disorder: Medication alone is insufficient; CBT is the cornerstone of treatment 6
2. Assuming lamotrigine is necessary without clear indication: Verify the diagnosis that prompted its prescription
3. Missing the suicidality screening requirement: The FDA mandates close monitoring for suicidal ideation with atomoxetine in young patients 1
4. Failing to coordinate multidisciplinary care: The APA guideline emphasizes that eating disorders require coordinated medical, psychiatric, psychological, and nutritional expertise 6

Bottom Line

Atomoxetine is appropriate for ADHD with comorbid anxiety, but this treatment plan fails to adequately address binge-eating disorder with evidence-based psychotherapy. Lamotrigine requires diagnostic justification. The optimal approach combines atomoxetine (or potentially lisdexamfetamine) with eating disorder-focused CBT, while reconsidering the necessity of lamotrigine based on confirmed psychiatric diagnoses.